FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4245752272> ?p ?o ?g. }

• W4245752272 abstract "You have accessJournal of UrologyBladder Cancer: Detection and Screening1 Apr 20121273 EVALUATION OF VITAMIN E AND SELENIUM SUPPLEMENTATION ON THE PREVENTION OF BLADDER CANCER IN SWOG-COORDINATED SELECT Yair Lotan, Phyllis Goodman, Ramy Youssef, Robert Svatek, Shahrokh Shariat, Catherine Tangen, Ian M. Thompson, and Eric A. Klein Yair LotanYair Lotan Dallas, TX More articles by this author , Phyllis GoodmanPhyllis Goodman Seattle, WA More articles by this author , Ramy YoussefRamy Youssef Dallas, TX More articles by this author , Robert SvatekRobert Svatek San Antonio, TX More articles by this author , Shahrokh ShariatShahrokh Shariat New York, NY More articles by this author , Catherine TangenCatherine Tangen Seattle, WA More articles by this author , Ian M. ThompsonIan M. Thompson San Antonio, TX More articles by this author , and Eric A. KleinEric A. Klein Cleveland, OH More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2012.02.1605AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Epidemiological and biological evidence suggest a preventative effect of selenium and vitamin E on bladder cancer. The objective of this study was to assess the effect of selenium, vitamin E, or the combinationon bladder cancer development. METHODS This was a secondary analysis of the randomized, placebo-controlled trial (Selenium and Vitamin E Cancer Prevention Trial [SELECT]) which included 34,887 men randomly assigned to four groups (selenium, vitamin E, selenium + vitamin E, and placebo) in a double-blind fashion between August 22, 2001, and June 24, 2004. The primary end point was bladder cancer incidence as determined by routine clinical management. RESULTS Within a median follow-up of 7.1 years (interquartile range, 6.4 – 8.0 years), 224 bladder cancer cases were recorded. Bladder cancer cases were older, more likely to be Caucasian and to have a smoking history compared to non bladder cancer subjects. Most cancers were urothelial and non-muscle invasive cancers. There were no significant differences in bladder cancer incidence among subjects in the placebo, selenium, vitamin E or selenium+vitamin E arms (placebo, n=53; vitamin E, n=56, HR=1.05 (0.64, 1.73), p=0.79; selenium, n=60, HR=1.13 (0.70, 1.84), p=0.52; vitamin E + selenium, n=55, HR=1.05 (0.63, 1.70, p=0.86). CONCLUSIONS This secondary analysis found no preventative effect of selenium or vitamin E, alone or in combination on bladder cancer in this population of men. Further studies are necessary to assess the effect in females and at different doses and formulations. Table 1. Baseline Characteristics – SELECT Bladder Cancers Characteristic All SELECT No Bladder Cancer Bladder Cancer p-value 34,887 34,663 224 Age Median (IQ range) 62(58,67) 67(58,72) 67(62,72) <.001 50 - 54 1480(4.2%) 1476(4.3%) 4(1.8%) 55 – 59 11,172(32.0%) 11,144(32.2%) 28(12.5%) 60 – 64 9,174(26.3%) 9,124(26.3%) 50(22.3%) 65 – 69 6,859(19.7%) 6,799(19.6%) 60(26.8%) 70 – 74 3,950(11.3%) 3,903(11.3%) 47(21.0%) 75 + 2,252(6.5%) 2,217(6.4%) 35(15.6%) Race White 27,571(79.0%) 27,367(79.0%) 204(91.0%) <.001 African American (non-Hispanic) 4,318(12.4%) 4,304(12.4%) 14(6.3%) Hispanic (non-AA) 1,940(5.6%) 1,939(5,6%) 1(0.5%) Hispanic (AA) 361(1.0%) 359(1.0%) 2(0.9%) Other 697(2.0%) 694(2.0%) 3(1.4%) Education < HS graduate 2,339(6.7%) 2,323(6.7%) 16(7.1%) <.001 HS graduate 5,343(15.3%) 5,297(15.3%) 46(20.5%) Vocational/some college 9,355(26.8%) 9,281(26.8%) 74(33.0%) College graduate 6,605(18.9%) 6,575(19.0%) 30(13.4%) Post-college 10,910(31.3%) 10,853(31.3%) 57(25.5%) Missing 335(1.0%) 334(1.0%) 1(0.5%) Smoking Status Never 15,110(43.3%) 15,056(43.4%) 54(24.1%) <.001 Former 17,053(49.0%) 16,899(48.8%) 154(68.8%) Current 2,700(7.7%) 2,684(7.7%) 16(7.1%) Missing 24(0.1%) 24(0.0%) 0(0.0%) 1 p-values based on Cox proportional hazards model parameterized as follows: Age (continuous); race (white vs. other), education (≤ high school vs. some vocational/some college vs. college graduate vs. post-college education) smoking (never vs. former vs. current). Missing values excluded. Table 2. Bladder Cancers Detected Placebo Vitamin E Selenium Combination Years of Follow-up (median, IQR) 7.0(6.1, 8.0) 7.0(6.0, 8.0) 7.0(6.0, 8.0) 7.0(6.0, 8.0) No. of Bladder Cancers 53 56 60 55 Stage CIS 3 4 4 3 TA 32 26 30 36 T1 10 18 19 7 ≥ T1 6 6 6 7 Unknown 2 2 1 2 Grade Well differentiated 21 18 23 29 Moderately differentiated 9 7 10 5 Poorly differentiated 22 29 26 19 Unknown 1 2 1 2 N-stage N0 3 2 3 5 N1 3 2 1 0 NX 47 52 56 50 M-stage M0 2 0 3 3 M1 3 3 0 1 MX 48 53 57 51 Histology Urothelial cell 51 53 59 50 Squamous cell 1 0 1 0 Adenocarcinoma 0 0 0 1 Small cell 0 1 0 0 Other/Unknown 1 2 0 4 Deaths (cause) Bladder cancer 6 6 3 3 Other cause 5 3 4 5 1 p-values based on Cox proportional hazards model parameterized as follows © 2012 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 187Issue 4SApril 2012Page: e515-e516 Advertisement Copyright & Permissions© 2012 by American Urological Association Education and Research, Inc.MetricsAuthor Information Yair Lotan Dallas, TX More articles by this author Phyllis Goodman Seattle, WA More articles by this author Ramy Youssef Dallas, TX More articles by this author Robert Svatek San Antonio, TX More articles by this author Shahrokh Shariat New York, NY More articles by this author Catherine Tangen Seattle, WA More articles by this author Ian M. Thompson San Antonio, TX More articles by this author Eric A. Klein Cleveland, OH More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ..." @default.
• W4245752272 created "2022-05-12" @default.
• W4245752272 creator A5001069772 @default.
• W4245752272 creator A5001359178 @default.
• W4245752272 creator A5015887484 @default.
• W4245752272 creator A5016811631 @default.
• W4245752272 creator A5026563364 @default.
• W4245752272 creator A5035404437 @default.
• W4245752272 creator A5041923034 @default.
• W4245752272 creator A5079401169 @default.
• W4245752272 date "2012-04-01" @default.
• W4245752272 modified "2023-09-27" @default.
• W4245752272 title "1273 EVALUATION OF VITAMIN E AND SELENIUM SUPPLEMENTATION ON THE PREVENTION OF BLADDER CANCER IN SWOG-COORDINATED SELECT" @default.
• W4245752272 doi "https://doi.org/10.1016/j.juro.2012.02.1605" @default.
• W4245752272 hasPublicationYear "2012" @default.
• W4245752272 type Work @default.
• W4245752272 citedByCount "1" @default.
• W4245752272 countsByYear W42457522722014 @default.
• W4245752272 crossrefType "journal-article" @default.
• W4245752272 hasAuthorship W4245752272A5001069772 @default.
• W4245752272 hasAuthorship W4245752272A5001359178 @default.
• W4245752272 hasAuthorship W4245752272A5015887484 @default.
• W4245752272 hasAuthorship W4245752272A5016811631 @default.
• W4245752272 hasAuthorship W4245752272A5026563364 @default.
• W4245752272 hasAuthorship W4245752272A5035404437 @default.
• W4245752272 hasAuthorship W4245752272A5041923034 @default.
• W4245752272 hasAuthorship W4245752272A5079401169 @default.
• W4245752272 hasConcept C120665830 @default.
• W4245752272 hasConcept C121332964 @default.
• W4245752272 hasConcept C121608353 @default.
• W4245752272 hasConcept C124490489 @default.
• W4245752272 hasConcept C126322002 @default.
• W4245752272 hasConcept C142724271 @default.
• W4245752272 hasConcept C143998085 @default.
• W4245752272 hasConcept C191897082 @default.
• W4245752272 hasConcept C192562407 @default.
• W4245752272 hasConcept C204787440 @default.
• W4245752272 hasConcept C27081682 @default.
• W4245752272 hasConcept C2780234812 @default.
• W4245752272 hasConcept C2780352672 @default.
• W4245752272 hasConcept C553756173 @default.
• W4245752272 hasConcept C61511704 @default.
• W4245752272 hasConcept C71924100 @default.
• W4245752272 hasConcept C74909509 @default.
• W4245752272 hasConceptScore W4245752272C120665830 @default.
• W4245752272 hasConceptScore W4245752272C121332964 @default.
• W4245752272 hasConceptScore W4245752272C121608353 @default.
• W4245752272 hasConceptScore W4245752272C124490489 @default.
• W4245752272 hasConceptScore W4245752272C126322002 @default.
• W4245752272 hasConceptScore W4245752272C142724271 @default.
• W4245752272 hasConceptScore W4245752272C143998085 @default.
• W4245752272 hasConceptScore W4245752272C191897082 @default.
• W4245752272 hasConceptScore W4245752272C192562407 @default.
• W4245752272 hasConceptScore W4245752272C204787440 @default.
• W4245752272 hasConceptScore W4245752272C27081682 @default.
• W4245752272 hasConceptScore W4245752272C2780234812 @default.
• W4245752272 hasConceptScore W4245752272C2780352672 @default.
• W4245752272 hasConceptScore W4245752272C553756173 @default.
• W4245752272 hasConceptScore W4245752272C61511704 @default.
• W4245752272 hasConceptScore W4245752272C71924100 @default.
• W4245752272 hasConceptScore W4245752272C74909509 @default.
• W4245752272 hasIssue "4S" @default.
• W4245752272 hasLocation W42457522721 @default.
• W4245752272 hasOpenAccess W4245752272 @default.
• W4245752272 hasPrimaryLocation W42457522721 @default.
• W4245752272 hasRelatedWork W2088198842 @default.
• W4245752272 hasRelatedWork W2313462236 @default.
• W4245752272 hasRelatedWork W2331625692 @default.
• W4245752272 hasRelatedWork W2376268022 @default.
• W4245752272 hasRelatedWork W2588194483 @default.
• W4245752272 hasRelatedWork W2919719141 @default.
• W4245752272 hasRelatedWork W2969049179 @default.
• W4245752272 hasRelatedWork W3043892729 @default.
• W4245752272 hasRelatedWork W3180752622 @default.
• W4245752272 hasRelatedWork W6007998 @default.
• W4245752272 hasVolume "187" @default.
• W4245752272 isParatext "false" @default.
• W4245752272 isRetracted "false" @default.
• W4245752272 workType "article" @default.